Related Experiment Video
Updated: Feb 3, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
[A Case of Refractory Pulmonary Enteric Adenocarcinoma with EGFR Sensitive Mutation]
Xinyi Wang1, Ning Mu1, Feng'e Li1
1Department of Oncology 5, Tianjin Union Medical Center (The First Affiliated Hospital of Nankai University), Tianjin 300121, China.
None:
Pulmonary enteric adenocarcinoma (PEAC) is a distinct subtype of non-small cell lung cancer (NSCLC) whose histomorphology and immunophenotype closely resemble those of metastatic colorectal adenocarcinoma; its pathogenesis and standard treatment strategies have yet to be clearly established. Here, we reported a case of PEAC harboring epidermal growth factor receptor (EGFR) exon 19 deletion mutation with high programmed cell death ligand 1 (PD-L1) expression. The patient showed no meaningful response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs), including the first-generation (Icotinib), the second-generation (Afatinib) and the third-generation (Aumolertinib). Trophoblast cell surface antigen 2-antibody-drug conjugate (TROP2-ADC) and immune checkpoint inhibitors (ICIs) combined with Bevacizumab also resulted in limited efficacy. Based on the clinical features and treatment response of this case, we reviewed the published literature about the pathological characteristics, mutational landscape, and current therapeutic approaches for PEAC, with a particular focus on the therapeutic challenges and future research directions for EGFR-mutant PEAC, aiming to provide insights for clinical practice and further studies. .
More Related Videos
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Viral Mutations
Mutation, Gene Flow, and Genetic Drift
Mutations in Microorganisms
Point and Frameshift Mutations

